Skip to content

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Prevention of Coronary Slow Flow or No-Reflow During Elective Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03406832
Acronym
NOSLOWFLOW-Ⅱ
Enrollment
1000
Registered
2018-01-23
Start date
2018-01-08
Completion date
2019-12-31
Last updated
2019-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Segment Elevation Myocardial Infarction, Elective Percutaneous Coronary Intervention

Keywords

Prevention, Slow flow, No reflow, Nitroprusside, Tirofiban

Brief summary

Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during EPCI.

Interventions

Intracoronary infusion 50\ 100μg each time (repeated)

Intracoronary infusion 10μg/kg for single time

Intracoronary infusion 2ml for single time

Sponsors

Anyang Regional Hospital
CollaboratorOTHER
Huaihe Hospital of Henan University
CollaboratorOTHER
The First Affiliated Hospital of Henan University of Science and Technology
CollaboratorOTHER
Yellow River Sanmenxia hospital
CollaboratorUNKNOWN
The Peoples' Hospital of Jiaozuo City
CollaboratorOTHER
Jincheng People's Hospital
CollaboratorOTHER
The second people's Hospital of Jiyuan
CollaboratorUNKNOWN
Kaifeng Central Hospital
CollaboratorOTHER
Lushan People's Hospital
CollaboratorUNKNOWN
Nanyang Central Hospital
CollaboratorOTHER
The Second People's Hospital of Pingdingshan
CollaboratorUNKNOWN
Shenma Medical Group General Hospital
CollaboratorOTHER
Puyang People's Hospital
CollaboratorUNKNOWN
Puyang Oilfield General Hospital
CollaboratorOTHER
The First People's Hospital of Shangqiu
CollaboratorUNKNOWN
Yanshi People's Hospital
CollaboratorUNKNOWN
The First People's Hospital of Xinmi
CollaboratorUNKNOWN
First Affiliated Hospital of Xinjiang Medical University
CollaboratorOTHER
Xinyang Central Hospital
CollaboratorOTHER
People's Hospital of Zhengzhou University
CollaboratorOTHER
Zhengzhou First People's Hospital
CollaboratorUNKNOWN
Chinese Academy of Medical Sciences, Fuwai Hospital
CollaboratorOTHER
Zhengzhou Central Hospital
CollaboratorOTHER
The 99th Central Hospital of the People's Liberation Army
CollaboratorUNKNOWN
Zhoukou Central Hospital
CollaboratorOTHER
The First People's Hospital of Zhumadian
CollaboratorUNKNOWN
Zhumadian Central Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ischemic symptoms \< 2 weeks (\> 24 hours) * Continued ischemic chest pain \> 30min * ST-segment elevation ≥ 0.1 millivolt in 2 or more contiguous leads on the 12-lead ECG or new left bundle branch block (LBBB) * Detection of a rise of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) * Elective coronary artery angiography was planned.

Exclusion criteria

* Emergency thrombolytic therapy was performed before elective coronary artery angiography * Cardiogenic shock with no response to hypervolemic treatment or vasopressor * Severe cardiomyopathy or valvular disease requiring intervention * Coronary ectasia * Severe heart failure * Contraindication or allergy to antiplatelet drugs * Contraindication or allergy to experimental drugs * Unable to receive at least 1 year of dual antiplatelet therapy * Active bleeding or extreme-risk for major bleeding * Severe liver or renal failure * Life expectancy \< 1 year * Unable or unwilling to provide informed consent * Women of child bearing potential * Under 18 years of age * Hemoglobin \< 90g/L * Platelet count \< 100×10\^9/L * Can not cooperate (with mental disorders or cognitive disorders)

Design outcomes

Primary

MeasureTime frameDescription
Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow grade1 minute after stent implantation; 1 minute after balloon dilatationgrade 0, no myocardial blush or contrast density; grade 1, minimal myocardial blush or contrast density; grade 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery; grade 3, normal myocardial blush or contrast density comparable with that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery.
Coronary TIMI frame count1 minute after stent implantation; 1 minute after balloon dilatationA continuous measurement assessing flow in the epicardial arteries.
Slow flow / no-reflow phenomenon1 minute after stent implantation; 1 minute after balloon dilatationSlow flow phenomenon means delayed progression or lack of contrast medium through the coronary tree.

Secondary

MeasureTime frameDescription
Main adverse cardiovascular and cerebrovascular events (MACCE)at 1 day post-PCI, at follow up of 1, 3, 6,12 months post-PCIDeath, Cardiac death, Rehospitalization (Heart failure) , Non-fatal myocardial infarction, Target vessel myocardial infarction, Target lesion revascularization, Target vessel revascularization, Ischemic-driven revascularization, Stent thrombosis, Bleeding, Cerebrovascular events, etc.

Countries

China

Contacts

Primary ContactChunguang Qiu, Phd
qcg123@163.com+86-13803898806
Backup ContactLiang Pan, MD
huzhoupanliang@gmail.com+86-15003851743

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026